Shire plc: Results of the Annual General Meeting Held on April 28, 2009
SHPGY), the global specialty biopharmaceutical company, announces that at its
Annual General Meeting today, all resolutions contained in the notice of
meeting were duly passed and the results of the poll are as follows:
For* Against Withheld**
1. To receive the
Company's accounts
together with the
director's and
auditor's reports 385,589,148 2,271,000 26,380
2. To approve the
Remuneration Report 307,647,526 60,796,610 19,442,392
3. To elect Dr Barry
Price as a Director
of the Company 356,441,471 31,425,618 19,439
4. To re-appoint
Deloitte LLP as
Auditors of the
Company 387,555,848 311,630 19,050
5. To authorize the
Audit, Compliance
and Risk Committee
to determine the
remuneration of the
Auditors 387,180,598 671,746 34,184
6. To authorize the
allotment of shares 332,997,412 54,868,377 20,739
7. To authorize the
disapplication of
pre-emption rights 387,558,665 297,124 30,739
8. To authorize market
purchases 387,693,316 173,212 20,000
* These figures include discretionary votes
** A vote “withheld” is not a vote in law and is not counted in the
calculation of the votes “for” or “against” a resolution.
Two copies of all resolutions passed, other than resolutions concerning
ordinary business, will shortly be submitted to the UK Listing Authority and
will be available for inspection at the UK Listing Authority’s Document
Viewing Facility, which is situated at the Financial Services Authority, 25
The North Colonnade, Canary Wharf,
Notes to Editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit hyperactivity
disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)
diseases as well as opportunities in other therapeutic areas to the extent
they arise through acquisitions. Shire’s in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of products with strategically
aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website:
http://www.shire.com.
For further information please contact:
Shire plc:
Tony Guthrie,
Deputy Company Secretary,
+44(0)1256-894746
Investor Relations
Clea Rosenfeld (Rest of the World)
+44-1256-894-160
Eric Rojas (North America)
+1-617-551-9715
Media
Jessica Mann (Rest of the World)
+44-1256-894-280
Matthew Cabrey (North America)
+1-484-595-8248
Jessica Cotrone (North America)
+1-617-613-4640
SOURCE Shire Plc
